Literature DB >> 9637514

Role of mucosal immunity in herpes simplex virus infection.

N A Kuklin1, M Daheshia, S Chun, B T Rouse.   

Abstract

This study evaluates whether the vaginal mucosal surface of immunized mice can prevent invasion by herpes simplex virus (HSV) and aims to identify immune components that affect immunity after challenge at the vaginal mucosa. Despite the induction of both IgA and IgG vaginal Ab following immunization with recombinant vaccinia virus vectors expressing either glycoproteins B or D, viral infection occurred in most animals even after minimal viral dose challenge. Challenged immune animals, including those genetically unable to generate anti-HSV Ab, survived and showed few if any clinical signs of infection. Experiments with T cell subtype knockout animals and depletion with T cell subset-specific MAb indicated that immunity following vaginal challenge was principally dependent on the function of CD4+ T cells. Our results indicate that anti-HSV vaccines may not provide barrier immunity at the vaginal mucosal site but may be adequate to minimize clinical expression of disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637514

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.

Authors:  Anthony B Nesburn; Ilham Bettahi; Gargi Dasgupta; Alami Aziz Chentoufi; Xiuli Zhang; Sylvaine You; Naoyuki Morishige; Andrew J Wahlert; Donald J Brown; James V Jester; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

5.  Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Authors:  Alison J Johnson; Chin-Fun Chu; Gregg N Milligan
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus.

Authors:  Christopher D Pack; Malgorzata Gierynska; Barry T Rouse
Journal:  Hum Vaccin       Date:  2008-09-28

7.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

8.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

9.  Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

Authors:  Ali A Ashkar; Stefan Bauer; William J Mitchell; Jeff Vieira; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

Authors:  Norifumi Iijima; Melissa M Linehan; Melodie Zamora; Debbie Butkus; Robert Dunn; Marilyn R Kehry; Terri M Laufer; Akiko Iwasaki
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.